Smoking prevalence and association with sociodemographic variables in cancer clinical trial participants.
Cary A PresantCathee TillRiha VaidyaKimlin Tan AshingGraham W WarrenVirginia SunRavi SalgiaErminia MassarelliJoanne E MortimerSumanta Kumar PalTanya Barauskas DorffArya AminiLoretta ErhunmwunseeTanyanika PhillipsDawn L HershmanJoseph M UngerPublished in: Cancer (2024)
In the first comprehensive evaluation of smoking status among trial participants enrolled in National Cancer Institute network group treatment trials, nearly half reported ever smoking and one in six reported current or recent smoking. Smoking was more common among vulnerable population patients defined by demographic and socioeconomic factors. Tobacco use should be routinely assessed and reported in clinical trials to help reduce the negative cancer and overall health effects of persistent tobacco use and to address disparities among patients with cancer.